Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis

H J Schmitt, E M Bernard, M Häuser, D Armstrong, H J Schmitt, E M Bernard, M Häuser, D Armstrong

Abstract

Invasive pulmonary aspergillosis is a major life-threatening complication among transplant recipients and patients receiving cancer chemotherapy. In a rat model of progressive pulmonary aspergillosis that is characterized by hyphal bronchopneumonia, aerosol amphotericin B (aero-AmB; 1.6 mg/kg given 2 days before infection) significantly delayed mortality in rats compared with animals in a control group. The first death in the aero-AmB-treated group occurred on day 11, by which time seven of the eight control animals had died. The same dose of aero-AmB given as treatment (1.6 mg/kg given 24 h after infection and then daily for 6 days) was also effective. In this trial, eight of the ten animals treated with aero-AmB survived for 7 days, whereas only one of ten control animals survived. Colony counts in lung homogenates obtained 24 h after infection showed an 80-fold reduction in the number of viable spores in animals that had received 6.4-mg/kg doses of aero-AmB 2 days prior to infection. At 48 h after administering a single 1.6- or 3.2-mg/kg dose of aero-AmB, mean lung concentrations were 2.79 and 5.22 micrograms/g of tissue, respectively. We conclude, therefore, that aero-AmB kills inhaled spores and delays the progression of pulmonary aspergillosis by inhibiting mycelial proliferation.

References

    1. Am Rev Respir Dis. 1968 Jul;98(1):87-92
    1. N Engl J Med. 1964 Dec 17;271:1281-5
    1. Am Rev Respir Dis. 1972 Feb;105(2):306-7
    1. N Engl J Med. 1976 Dec 2;295(23):1319-20
    1. Am Rev Respir Dis. 1978 Jul;118(1):49-53
    1. Ann Intern Med. 1979 Jan;90(1):4-9
    1. Am J Med. 1980 Mar;68(3):389-94
    1. Am J Epidemiol. 1982 Sep;116(3):430-7
    1. Ann Ophthalmol. 1982 Jan;14(1):67-72
    1. Urology. 1983 Mar;21(3):295-7
    1. Am J Med. 1984 Jan;76(1):162-6
    1. Am J Med. 1984 May 15;76(5A):42-52
    1. J Infect Dis. 1985 Nov;152(5):1037-43
    1. Ophthalmology. 1985 Oct;92(10):1440-4
    1. Cancer. 1986 Mar 15;57(6):1092-6
    1. Pediatr Infect Dis. 1986 Mar-Apr;5(2):264-8
    1. Presse Med. 1986 Feb 1;15(4):153-6
    1. Cancer. 1986 Jul 15;58(2):366-71
    1. Am J Med. 1986 Jul;81(1):24-8
    1. Cancer. 1986 Sep 1;58(5):1047-54
    1. N Engl J Med. 1987 Oct 29;317(18):1105-8
    1. Am J Med. 1987 Oct;83(4):709-18
    1. Antimicrob Agents Chemother. 1987 Dec;31(12):1867-70
    1. Antimicrob Agents Chemother. 1988 May;32(5):780-1
    1. Br Med J. 1956 Oct 6;2(4996):783-6
    1. Lancet. 1958 Mar 22;1(7021):621-2
    1. Am Rev Respir Dis. 1959 Sep;80:441-2
    1. Tubercle. 1970 Jun;51(2):184-91

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅